Rocket Lab USA에 대한 매도 수량은 투자자에게 Rocket Lab USA의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Rocket Lab USA (NASDAQ:RKLB) 주식, 공매도 수량 보고

Rocket Lab USA

Rocket Lab USA Inc is engaged in space, building rockets, and spacecraft. It provides end-to-end mission services that provide frequent and reliable access to space for civil, defense, and commercial markets. It designs and manufactures the Electron and Neutron launch vehicles and Photon satellite platform. Rocket Lab's Electron launch vehicle has delivered multiple satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. The business operates in two segments being Launch Services and Space systems. Geographically it serves Japan, Germany, rest of the world and earns key revenue from the United States.

Mid Cap

News

Movers

Trading Ideas

BILI

RKLB

XPEV

지난주, 중국 중앙은행이 은행의 지급준비율(RRR)을 50bp(베이시스 포인트) 또는 0.5%포인트 인하하기로 발표하면서 미국에 상장된 중국 기업들의 주가가 전반적으로 상승했다.

중국 주식이 우세 - 빌리빌리와 샤오펑은 지난주 최고 성과를 보여준 7개 중형주 중 일부 (9월 23일-9월 27일)

ASTS

INTA

LITE

LOAR

QFIN

다음은 지난주 큰 폭의 상승세를 보인 7개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? AST 스페이스모바일(NASDAQ:ASTS)의 주가는 회사가 9월 초 위성 5개를 발사할 예정이라고 발표한 후 48.26% 급등했다. 

AST 스페이스모바일 및 로켓 랩은 지난주 최고 성과를 보여준 7개 중형주 중 일부 (8월 11일-8월 17일)

Earnings

SPACE

Guidance

After-Hours Center

General

로켓 랩 USA(NASDAQ:RKLB)는 목요일 시장 마감 후 2분기 재무 결과를 발표하고 시간외 거래에서 주가가 10% 이상 상승했다. 이번 분기의 주요 하이라이트는 다음과 같다.

로켓 랩의 주식은 예상보다 좋은 2분기 실적으로 시간외 거래에서 10% 이상 상승

Rocket Lab USA Inc

Ratings for Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Indie Semiconductor, presenting an average target of $8.75, a high estimate of $12.00, and a low estimate of $7.00. Observing a downward trend, the current average is 18.6% lower than the prior average price target of $10.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1730840415_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Indie Semiconductor among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$9.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Ross Seymore</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Suji Desilva</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$7.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Indie Semiconductor. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Indie Semiconductor compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Indie Semiconductor's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Indie Semiconductor's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/INDI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Indie Semiconductor analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Indie Semiconductor: A Closer Look</h2>
Indie Semiconductor Inc is empowering the Autotech revolution with next-generation automotive semiconductors and software platforms. It focuses on edge sensors for advanced Driver Assistance Systems including LiDAR, connected car, user experience, and electrification applications. These technologies represent the core underpinnings of both electric and autonomous vehicles, while the advanced user interfaces transform the in-cabin experience to mirror and seamlessly connect to the mobile platforms. Geographically, the company generates majority of its revenue from Greater China and rest from United States, Europe, South Korea and other regions.
<h3>Unraveling the Financial Story of Indie Semiconductor</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Indie Semiconductor displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 0.47%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Indie Semiconductor's net margin excels beyond industry benchmarks, reaching -36.6%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Indie Semiconductor's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -4.24%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Indie Semiconductor's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.39%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Indie Semiconductor's debt-to-equity ratio is below the industry average at 0.39, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

INDI

Key Takeaways From Indie Semiconductor Analyst Ratings

<a href="https://www.bloomberg.com/news/articles/2024-11-05/golub-capital-combines-four-clos-into-biggest-reset-on-record">https://www.bloomberg.com/news/articles/2024-11-05/golub-capital-combines-four-clos-into-biggest-reset-on-record</a>
Asset manager Golub Capital issued the largest reset of a collateralized loan obligation on record late last <a href="https://www.bloomberg.com/news/terminal/SM8MWAT0G1KW">week</a>, created through an amalgamation of multiple CLOs.
Golub fused four different CLOs together, a type of transaction that's been performed <a href="https://www.bloomberg.com/news/terminal/Q5AINZT0G1KZ">at least once before</a>. Its combination formed a massive $2.2 billion reset, surpassing a $2 billion <a href="https://www.bloomberg.com/news/terminal/QPD0N5T1UM11">record </a>previously set by Antares in 2021, according to data from <a href="https://www.bloomberg.com/quote/JPM:US">JPMorgan Chase &amp; Co.</a>

GBDC

'Golub Capital Combines Four CLOs Into Biggest Reset On Record; The $2.2B Deal Surpasses Formerly Largest Antares Reset; Nearly $30B Of CLO Resets Priced In October 2024' - Bloomberg News

<a href="https://www.bloomberg.com/news/articles/2024-11-05/apple-to-face-first-eu-fine-under-bloc-s-digital-markets-act">https://www.bloomberg.com/news/articles/2024-11-05/apple-to-face-first-eu-fine-under-bloc-s-digital-markets-act</a>
Apple Inc. is set to face the first-ever fine under the European Union's new digital antitrust rules for Big Tech, representing an escalation of a clash with regulators over the dominance of its hugely profitable App Store.

Legal

AAPL

'Apple To Face First EU Fine Under Bloc's Digital Markets Act' - Bloomberg News

By Doug Young
Yum China Holdings Ltd.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/yumc#NYSE">YUMC</a>) announced on Monday it will boost its spending on repurchasing its shares and paying dividends, as it continued to deliver solid revenue and core operating profit growth of 5% and 18%, respectively, in the third quarter despite a challenging operating environment. It said the results demonstrated the effectiveness of its strategy and ability to outperform in a challenging and fluid environment.
Yum China also said it was further raising its cash allocation for share buybacks and dividends, often referred to by companies as &ldquo;returning value to shareholders,&rdquo; to $4.5 billion over the three years from 2024 to 2026 from a previous commitment of $3 billion.
The company has already spent nearly three times as much on shareholder returns in the first nine months of this year as it did in the same period last year, including over $1 billion in share repurchases and $187 million in quarterly dividends.
Yum China has continually repurchased its shares since it was spun off from its former parent,&nbsp;Yum Brands&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/yum#NYSE">YUM</a>) in 2016. The company has grown rapidly since Yum opened its first KFC in Beijing in 1987, and it is now the country&rsquo;s largest restaurant operator.
While share buybacks provide value to shareholder by reducing the size of a company&rsquo;s outstanding shares, Yum China said it canceled its repurchased shares, which is more beneficial to shareholder than other treatment. Yum China has bought back more than 27 million shares this year, around 7% of its total shares outstanding. That has helped its earnings per share (EPS) to grow more quickly than actual profit growth, with its EPS up 33% in this year&rsquo;s third quarter, ahead of the 22% rise in its actual net profit for the period.
Yum China&rsquo;s cumulative shareholder returns have exceeded $4 billion since it first listed in the U.S. in 2016. It picked up the pace sharply after making a second listing in Hong Kong in 2020. Yum China&rsquo;s cash position remains healthy, with net cash of $3.1 billion at the end of September. &nbsp;
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Asia

Markets

YUMC

NEWS WRAP: Yum China Boosts Returns To Shareholders On Strong Quarterly Results

Suze Orman, a well-known personal finance expert, has a simple but powerful message: Small spending habits can snowball into big financial setbacks. Over time, the decisions we make about seemingly insignificant purchases end up costing us hundreds or even thousands of dollars. According to Orman, learning to say &#8220;no&#8221; to our loved ones as well as to ourselves is one of the most difficult things.
Don't Miss:
<ul>
<li>According to Vanguard&#8217;s Advisor&#8217;s Alpha Study, working with a financial advisor can result in approximately 3% higher net returns annually,<a href="https://www.benzinga.com/money/3-percent-advantage-financial-advisor"> here are the benefits of partnering with a financial advisor and how to find the right one near you in minutes.</a></li>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.</li>
</ul>
<h2 class="wp-block-heading">The Little Mistakes That Add Up</h2>
Orman often discusses the hidden costs of our everyday spending habits. Grabbing a name-brand item or a small impulse buy at the grocery store may not seem like much in the moment, but a few extra dollars each trip quickly adds up to hundreds or even thousands annually.&nbsp;
The problem isn&#8217;t limited to groceries. Orman also points out how easy it is to let spending on other non-necessities slip by – buying individually wrapped snacks instead of in bulk, for example.&nbsp;
Trending: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
<h2 class="wp-block-heading">Why Cutting Back Matters</h2>
You might think, &#8220;I work hard; I deserve to splurge a little.&#8221; While there's truth to wanting to reward yourself, Orman urges people to think about what's really at stake. The more you spend on things you don&#8217;t truly need, the less you have for what's important – emergencies, retirement or peace of mind.
In one of her examples, Orman recalls <a href="https://www.benzinga.com/personal-finance/financial-advisors/24/10/41553671/the-wealthy-follow-suze-ormans-golden-rule-for-getting-rich-she-says-theres-1">buying a modest apartment</a> when she could have afforded a million-dollar penthouse. For her, the key was buying what she needed, not just what she could afford. It's a lesson she wishes more people would consider: focus on your needs, not your wants. Otherwise, the unexpected can leave you struggling financially.
Trending: <a href="https://www.benzinga.com/money/100k-cd">$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</a>
<h2 class="wp-block-heading">Say &#8220;No&#8221; To Loved Ones (And Yourself)</h2>
Saying &#8220;no&#8221; is hard, especially when it comes to family. But Orman believes it&#8217;s crucial if you&#8217;re serious about meeting your financial goals. You need the discipline to recognize when you're spending just because you can and know when that money could be better used elsewhere.
Orman isn't the only one with opinions on spending habits. The same is true for one of the wealthiest people on the planet, Warren Buffett, who is known for driving secondhand cars and <a href="https://www.benzinga.com/news/24/09/41107810/billionaire-warren-buffett-still-lives-in-an-old-corner-house-he-purchased-for-32k-i-couldnt-imagine">living in a modest home</a>. His prudence reminds us that living below our means can pave the way for long-term financial success.
See Also: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
<h2 class="wp-block-heading">Gen Z&#8217;s Take on Money</h2>
Orman has also offered her thoughts on Gen Z&#8217;s financial practices, arguing that they often place excessive <a href="https://www.benzinga.com/personal-finance/24/09/40778796/suze-orman-says-gen-zs-fashion-obsession-hinders-wealth-building-they-would-rather-dress-cool-go">emphasis on appearances rather than investing</a>. But not every expert agrees. While younger generations may spend money on social media influence or new clothing, many are also beginning to invest earlier than prior generations. They use social media platforms like TikTok and YouTube to build income streams, turning their creativity into cash.
Read Next:
<ul>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
</ul>

Personal Finance

If You Do This, Prepare To Spend Thousands On Non-Necessities, Says Suze Orman. Her Solution? Learn To Say "No" To Loved Ones

WIIM

THTX

Foghorn Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.

MediaAlpha shares are trading lower following a report from Wolfpack Research.

Deep-pocketed investors have adopted a bearish approach towards UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in UNH usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 52 extraordinary options activities for UnitedHealth Group. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 44% leaning bullish and 50% bearish. Among these notable options, 16 are puts, totaling $721,919, and 36 are calls, amounting to $2,134,986.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $480.0 to $650.0 for UnitedHealth Group during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for UnitedHealth Group's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of UnitedHealth Group's whale trades within a strike price range from $480.0 to $650.0 in the last 30 days. 
<h3>UnitedHealth Group Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730839752_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$17.05</td>
<td>$17.0</td>
<td>$17.0</td>
<td>$567.50</td>
<td>$278.8K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">173</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$17.15</td>
<td>$17.1</td>
<td>$17.1</td>
<td>$565.00</td>
<td>$237.6K</td>
<td style="text-align: right;">187</td>
<td style="text-align: right;">158</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$14.95</td>
<td>$14.5</td>
<td>$14.5</td>
<td>$565.00</td>
<td>$145.0K</td>
<td style="text-align: right;">148</td>
<td style="text-align: right;">241</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$11.05</td>
<td>$10.7</td>
<td>$11.05</td>
<td>$562.50</td>
<td>$102.7K</td>
<td style="text-align: right;">50</td>
<td style="text-align: right;">127</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$19.3</td>
<td>$19.2</td>
<td>$19.3</td>
<td>$557.50</td>
<td>$88.5K</td>
<td style="text-align: right;">174</td>
<td style="text-align: right;">97</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
<h3>Where Is UnitedHealth Group Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,471,322, the price of UNH is up by 1.84%, reaching $568.04.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 66 days from now.</li>
</ul>
<h3>What Analysts Are Saying About UnitedHealth Group</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $637.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald persists with their Overweight rating on UnitedHealth Group, maintaining a target price of $644. 
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on UnitedHealth Group with a target price of $650. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for UnitedHealth Group, targeting a price of $650. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for UnitedHealth Group, targeting a price of $650. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on UnitedHealth Group, maintaining a target price of $595. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for UnitedHealth Group, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

A Closer Look at UnitedHealth Group's Options Market Dynamics

Investors with a lot of money to spend have taken a bearish stance on Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SAVA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Cassava Sciences.
This isn't normal.
The overall sentiment of these big-money traders is split between 18% bullish and 54%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $179,025, and 7 are calls, for a total amount of $351,889.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $60.0 for Cassava Sciences over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Cassava Sciences's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Cassava Sciences's significant trades, within a strike price range of $15.0 to $60.0, over the past month.
<h3>Cassava Sciences Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730839747_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$10.95</td>
<td>$10.9</td>
<td>$10.9</td>
<td>$45.00</td>
<td>$104.6K</td>
<td>1.9K</td>
<td style="text-align: right;">134</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.45</td>
<td>$7.75</td>
<td>$7.76</td>
<td>$15.00</td>
<td>$77.5K</td>
<td>2.3K</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$10.95</td>
<td>$10.9</td>
<td>$10.9</td>
<td>$45.00</td>
<td>$71.9K</td>
<td>1.9K</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$9.0</td>
<td>$8.7</td>
<td>$8.7</td>
<td>$60.00</td>
<td>$43.4K</td>
<td>2.2K</td>
<td style="text-align: right;">104</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$9.0</td>
<td>$8.5</td>
<td>$8.7</td>
<td>$60.00</td>
<td>$42.6K</td>
<td>2.2K</td>
<td style="text-align: right;">153</td>
</tr>
</tbody>
</table>

<h3>About Cassava Sciences</h3>
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
After a thorough review of the options trading surrounding Cassava Sciences, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Cassava Sciences</h3>
<ul>
<li>With a volume of 1,410,319, the price of SAVA is down -7.39% at $23.93. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 2 days.</li>
</ul>
<h3>What Analysts Are Saying About Cassava Sciences</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $116.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a positive move, an analyst from HC Wainwright &amp; Co. has upgraded their rating to Buy and adjusted the price target to $116. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Cassava Sciences, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

SAVA

Unpacking the Latest Options Trading Trends in Cassava Sciences

Financial giants have made a conspicuous bullish move on Iovance Biotherapeutics. Our analysis of options history for Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) revealed 11 unusual trades.
Delving into the details, we found 45% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $234,150, and 5 were calls, valued at $414,807.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $7.5 to $15.0 for Iovance Biotherapeutics during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Iovance Biotherapeutics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Iovance Biotherapeutics's whale activity within a strike price range from $7.5 to $15.0 in the last 30 days. 
<h3>Iovance Biotherapeutics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730839741_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.3</td>
<td>$3.1</td>
<td>$3.3</td>
<td>$10.00</td>
<td>$141.9K</td>
<td>2.4K</td>
<td style="text-align: right;">433</td>
</tr>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$3.2</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$9.00</td>
<td>$135.0K</td>
<td>6.1K</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.5</td>
<td>$1.2</td>
<td>$1.49</td>
<td>$15.00</td>
<td>$64.8K</td>
<td>891</td>
<td style="text-align: right;">440</td>
</tr>
<tr>
<td>IOVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$4.0</td>
<td>$3.8</td>
<td>$3.9</td>
<td>$12.00</td>
<td>$46.8K</td>
<td>109</td>
<td style="text-align: right;">362</td>
</tr>
<tr>
<td>IOVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.0</td>
<td>$3.8</td>
<td>$3.8</td>
<td>$12.00</td>
<td>$45.6K</td>
<td>109</td>
<td style="text-align: right;">242</td>
</tr>
</tbody>
</table>

<h3>About Iovance Biotherapeutics</h3>
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Following our analysis of the options activities associated with Iovance Biotherapeutics, we pivot to a closer look at the company's own performance.
<h3>Iovance Biotherapeutics's Current Market Status</h3>
<ul>
<li>With a volume of 1,428,846, the price of IOVA is down -1.97% at $11.21. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 2 days.</li>
</ul>
<h3>What The Experts Say On Iovance Biotherapeutics</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $17.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from UBS lowers its rating to Buy with a new price target of $17.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Iovance Biotherapeutics options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

IOVA

Iovance Biotherapeutics Options Trading: A Deep Dive into Market Sentiment

ROKU

Reported Earlier, Roku 13G Filing Shows Sumitomo Mitsui Trust Group, Inc. Reported A 5.06% Stake In The Co As Of September 30, 2024

<a href="https://www.reuters.com/business/autos-transportation/stellantis-ceo-did-not-confirm-maserati-ev-plans-union-says-2024-11-05/">https://www.reuters.com/business/autos-transportation/stellantis-ceo-did-not-confirm-maserati-ev-plans-union-says-2024-11-05/</a>
Stellantis CEO Carlos Tavares has failed to confirm previously announced electrification plans for Maserati, Italian trade unionists said after meeting him on Tuesday, adding to concern about the loss-making luxury brand.
Tavares visited Maserati's plant in its hometown of Modena, but "no clear answers came" from his conversations with workers' representatives, Samuele Lodi and Stefania Ferrari of the FIOM-Cgil union said in a joint statement.
Lodi and Ferrari expressed concern that "contrary to what was previously communicated" to unions, the planned start of production in mid-2025 of the electric version of the MC 20 sports car was not mentioned.
"There was no mention of electric models, nor of other new models coming to the Modena plant," they said.
Tavares came to Modena with the new CEO of Maserati Santo Ficili, appointed this month.
Under its previous boss, Maserati announced plans to fully electrify its lineup by 2028, including with a new version of its Levante large SUV in 2027, and a new Quattroporte luxury sedan in 2028.
The Franco-Italian automaker has repeatedly denied speculation about a possible sale of Maserati, although Tavares has said the group cannot afford to keep brands that are not profitable.
Stellantis was not available for comment on the union statement.
In a note earlier on Tuesday it said it was pushing ahead with electrification and "finalising a strategic plan to take the (Maserati) brand back to the top of the sector, with a full pipeline of new products and technologies for the coming years".

STLA

'Stellantis CEO Did Not Confirm Maserati EV Plans, Union Says' - Reuters News

<a href="https://www.reuters.com/legal/google-defeats-lawsuit-over-gift-card-fraud-2024-11-05/#:~:text=Nov%205%20(Reuters)%20%2D%20A,of%20dollars%20stolen%20from%20victims.">https://www.reuters.com/legal/google-defeats-lawsuit-over-gift-card-fraud-2024-11-05/#:~:text=Nov%205%20(Reuters)%20%2D%20A,of%20dollars%20stolen%20from%20victims.</a>
A federal judge dismissed a proposed class action lawsuit accusing Google of illegally profiting from Google Play gift card scams by refusing to refund millions of dollars stolen from victims.
In a late Monday decision, U.S. District Judge Beth Labson Freeman said the plaintiff Judy May lost money because scammers induced her to buy gift cards, and failed to show that Google caused her losses or knew it was receiving stolen funds.
The San Jose, California-based judge also said Google was not liable for keeping 15% to 30% commissions on purchases that scammers made with the gift cards, because Google's conduct was unrelated to the original fraud.
May said she lost $1,000 in April 2021 when a scammer posing as a relative instructed her to contact a supposed government agent, who told her she was eligible for federal grant money if she bought Google Play gift cards.
The Brownsville, Indiana resident said she provided the codes on the back to cover supposed upfront costs, but the scammers used the codes to make purchases.
May said she would not have bought the cards had Google warned on the packaging about scams, and that anyone demanding payment with the cards was a scammer.
Lawyers for May did not immediately respond on Tuesday to requests for comment. Google, a unit of Alphabet, did not immediately respond to similar requests.
Freeman said May could try to refile her lawsuit, but dismissed a claim seeking triple damages for good. Alphabet is based in Mountain View, California.
In 2023, Americans lost $217 million in <a href="https://www.ftc.gov/system/files/ftc_gov/pdf/CSN-Annual-Data-Book-2023.pdf">gift card or reload card fraud, opens new tab</a>, according to the Federal Trade Commission.
The actual amount is likely much higher because the data cover only reported cases. Citing FTC data from 2021, May said Google Play cards account for about 20% of gift card scams.
&nbsp;
The case is May v Google LLC et al, U.S. District Court, Northern District of California, No. 24-01314.

GOOG

GOOGL

Reported Earlier, "Google Defeats Lawsuit Over Gift Card Fraud" - Reuters News

Fox Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) warrants a Buy rating, according to Goldman Sachs analyst Michael Ng.
On Monday, Fox reported <a href="https://www.benzinga.com/news/earnings/24/11/41715564/foxs-q1-earnings-revenue-and-eps-beat-political-ads-tubi-expansion-boosts-growth" target="_blank" rel="noreferrer noopener">fiscal first-quarter 2025</a> revenues of $3.56 billion, up from $3.21 billion a year ago, beating the analyst consensus of $3.37 billion. 
Ng maintains a <a href="https://www.benzinga.com/quote/FOXA/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $46 to $51</a>.
Cable Network Programming reported quarterly segment revenues of $1.6 billion, up by 15%. Television reported quarterly segment revenues of $1.95 billion, up 10%.
Also Read: <a href="https://www.benzinga.com/news/earnings/24/11/41714051/marriott-international-q3-earnings-china-market-weakness-drags-on-performance-adjusts-full-year-out" target="_blank" rel="noreferrer noopener">Marriott International Q3 Earnings: China Market Weakness Drags on Performance, Adjusts Full-Year Outlook</a>
Ng observed that Fox Corp outperformed in the first quarter of fiscal 2025, reporting EBITDA of $1.05 billion, above the expected $874 million consensus. This was driven largely by stronger-than-anticipated results in both its Cable Network Programming segment, which posted an EBITDA of $748 million, and its Television segment, which delivered $372 million.
The analyst attributed the Cable Network's success to operating expense control and Fox News Media's ratings. At the same time, Television gained from higher-than-expected political ad revenues, notably in local stations and the streaming platform Tubi, which grew 19% year-over-year.
He raised Fox's 12-month price target to $51 from $46, reflecting expectations of record political ad revenue for fiscal 2025 as Tubi's ad performance strengthens.
Ng highlighted Tubi's targeted advertising appeal in the FAST (free ad-supported streaming) category. He expects the platform to benefit from continued political ad spending.
Fox Corp anticipates Tubi's revenue to exceed $1 billion in fiscal 2025. That projection aligns with market estimates, underscoring the platform's long-term growth potential as digital ad budgets shift.
Price Action:&nbsp;FOXA stock is up 1.73% at $43.75 at&nbsp;the last check on Tuesday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41710271/roaring-kitty-stock-chewy-set-to-join-s-p-midcap-400-index-will-replace-stericycle" target="_blank" rel="noreferrer noopener">Roaring Kitty Stock Chewy Set to Join S&amp;P MidCap 400 Index, Will Replace Stericycle</a></li>
</ul>
Image: Shutterstock

Price Target

Reiteration

FOXA

Fox Corp's Political Ad Revenue Surges, Tubi Growth Sparks Analyst Optimism

Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has reportedly introduced a new incentive to promote car purchases to capitalize on <a target="_blank" href="https://www.benzinga.com/news/24/11/41738613/elon-musk-rejects-rumors-of-a-tesla-phone-but-says-the-ev-giant-will-have-to-make-one-if-this-happen" rel="noreferrer noopener">China's auto consumption stimulus.</a>
The EV giant is offering Chinese customers the chance to win a tour of its Giga Shanghai, <a target="_blank" href="https://cnevpost.com/2024/11/05/tesla-shanghai-plant-visit-as-purchase-incentive/" rel="noreferrer noopener">reported</a> CnEV Post.
The report, citing a post on Weibo, said that from now until December 3, those who order a new vehicle through the official trade-in program and take delivery within the contract period will be eligible.
Teslarati <a target="_blank" href="https://www.teslarati.com/tesla-china-giga-shanghai-tour-incentive/" rel="noreferrer noopener">reports</a> that ten winners will be selected for a special tour of Gigafactory Shanghai by December 3. Each winner can bring a friend and receive free round-trip airfare and one night's hotel accommodation.
In October, the gigafactory in Shanghai touched a new production milestone of 3 million cars.
Related: <a target="_blank" href="https://www.benzinga.com/news/24/10/41303692/teslas-giga-shanghai-hits-3-million-production-milestone-celebrates-with-red-model-rollout" rel="noreferrer noopener">Tesla's Giga Shanghai Hits 3 Million Production Milestone, Celebrates With Red Model Rollout</a>
Tesla had made the announcement via social media <a target="_blank" href="https://x.com/Tesla_Asia/status/1844709411983655249" rel="noreferrer noopener">platform</a> X.
"Giga Shanghai achieves 3 million production milestone," the company wrote with an adjoining image of the employees at the gigafactory in China celebrating the milestone with a red Tesla car in their midst.
Tesla China's Gigafactory Shanghai is the EV giant's largest by production volume, with an estimated annual output exceeding 950,000 vehicles, according to the third quarter 2024 Update Letter, Teslarati added. Giga Shanghai manufactures the Model 3 and Model Y for both the domestic Chinese market and international markets.
Meanwhile, Tesla has reportedly raised wages for all its employees at&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/giga-berlin" rel="noreferrer noopener">its gigafactory in Berlin</a>. Reuters reported that the wage hike has been in effect since the start of November. The factory in Berlin employs nearly 12,000 staff.
The Berlin factory is Tesla's only in Europe. Its current installed annual vehicle capacity is over 375,000 Model Ys.
Price Action: TSLA shares are trading higher by 4.39% to $253.13&nbsp;at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41741441/tesla-hikes-wages-by-4-for-giga-berlin-employees-report" target="_blank" rel="noreferrer noopener">Tesla Hikes Wages By 4% For Giga Berlin Employees: Report</a></li>
</ul>
Photo by betto rodrigues on Shutterstock

Equities

Emerging Markets

Tech

TSLA

Tesla Lures Chinese Buyers With Exclusive Giga Shanghai Tour Giveaway to Boost Sales: Report

In its third-quarter earnings report, NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) posted earnings <a href="https://www.benzinga.com/topic/semiconductors">of $3.45 per share</a>.
The company narrowly beat the consensus estimate of $3.43, with revenue <a href="https://www.benzinga.com/news/earnings/24/11/41730768/nxp-semiconductors-shares-dip-after-q3-results-eps-beat-revenues-in-line-q4-guidance-below-estimate">matching expectations at $3.25 billion</a>. That&#8217;s down from $3.43 billion year-over-year.
NXP Semiconductors CEO Kurt Sievers highlighted macro headwinds, particularly in Europe and the Americas, as a factor in the company's softer fourth-quarter guidance. He forecasts revenue between $3 billion and $3.2 billion and earnings between $2.93 and $3.33 per share, both below analyst expectations.
The earnings report has prompted varied reactions from analysts, who are assessing NXP's performance and outlook amidst global economic uncertainty.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41753325/wall-street-rallies-on-election-day-palantir-skyrockets-bitcoin-tops-70-000-whats-driving-">Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What&#8217;s Driving Markets Tuesday?</a>
<h2 class="wp-block-heading">Analyst Color Following NXPI Earnings</h2>
Truist analyst William Stein highlighted that, despite robust performance in the Mobile and Communications segments and a modest increase in Automotive revenue, significant weakness in the Industrial sector had a considerable impact on overall results.
Truist attributes this downturn to excess inventory levels, which have been a recurring concern in recent months. NXP&#8217;s inventory levels remained stable at approximately 145.3 days, contrary to the expected seasonal decline, with channel inventory slightly above management&#8217;s guidance.
Truist maintains a Buy rating and a $287 price target on the stock.
Demand trends in the third quarter, as highlighted by KeyBanc, showed stability in the Auto segment, while performance in the Industrial and IoT markets fell below expectations. Conversely, Mobile and Communications revenue slightly exceeded forecasts. 
Looking ahead, KeyBanc expects NXP to experience a revenue decline of 5% quarter-over-quarter in the fourth quarter, which is lower than consensus estimates and reflects ongoing macroeconomic challenges, particularly in Europe and the Americas.
Read Also: <a href="https://www.benzinga.com/general/biotech/24/11/41747104/novo-nordisk-q3-preview-will-285-million-weight-loss-bet-offset-bearish-charts">Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?</a>
Cantor Fitzgerald analyst C.J. Muse noted that the weakness in Industrial &amp; IoT resulted in lower gross margins, projected to hit new lows at 57.5%, a 70 basis point decline from the third quarter. 
Additionally, the reduced mix in Industrial segments is expected to lead to further margin compression, though NXP's prompt adjustment in operating expenses should help partially offset this impact. 
Despite the headwinds, Cantor reaffirmed its Overweight rating on NXP. Muse cites confidence in a gradual market recovery and NXP's ongoing structural transformation, which they believe is undervalued at present. The firm's price target remains at $270, reflecting a positive long-term outlook.
Oppenheimer analyst Rick Schafer maintained an Outperform rating on NXP, citing confidence in the company's long-term positioning despite near-term challenges. The firm remains optimistic about NXP's growth potential, driven by advancements in automotive content such as radar, BMS and processors, which they see as offsetting market softness.
Oppenheimer highlighted the European Semiconductor Manufacturing Company (ESMC) joint venture with TSMC, Bosch and Infineon broke ground on a new 300mm fab in Dresden, marking a significant long-term growth initiative.
In terms of the fourth quarter, Stifel analyst Tore Svanberg highlighted the softer outlook. Revenue guidance is at $3.10 billion—a 4.6% sequential decline and 8.3% below previous estimates.
Operating margins are expected to fall by 140 basis points quarter-over-quarter. Stifel maintains their Hold rating with a $260 price target.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NXPI has a 52-week high of $296.08 and a 52-week low of $178.19.
Read Also: 
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/11/41748843/trump-holds-edge-in-betting-markets-on-election-day-while-experts-call-tight-race-for-harris">Trump Holds Edge In Betting Markets On Election Day, While Experts Call Tight Race For Harris</a></li>
</ul>
Image via NXP Semiconductors

NXPI

NXP Semiconductors Q3 Earnings: Analysts Weigh In On Revenue Decline, Weak Q4 Guidance

SNDL

SNDL shares are trading higher after the company reported better-than-expected Q3 revenue results.

IRON

Disk Medicine shares are trading higher. HC Wainwright & Co. Reiterated a Buy rating on the stock.

On Tuesday, Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell therapy for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41745039/beam-therapeutics-to-present-data-across-hematology-franchise-including-first-clinical-data-for-be" rel="noreferrer noopener">sickle cell disease (SCD)</a>.
Eight of these patients have been dosed with BEAM-101, while the other enrolled patients are going through pre-transplant stages, including cell collection and drug product manufacturing.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40375976/gene-editing-korro-bios-preclinical-data-best-in-class-analyst-initiates-with-outperform-rating" rel="noreferrer noopener">Gene Editing Korro Bio&#8217;s Preclinical Data &#8216;Best-In-Class&#8217;, Analyst Initiates With Outperform Rating</a>
In a company <a target="_blank" href="https://investors.beamtx.com/static-files/4e9eea51-c299-4b58-965a-87a5a8c3b62f" rel="noreferrer noopener">presentation</a>, preliminary safety data (N=6) showed an initial safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant (HSCT).
The company said that one patient died due to respiratory failure likely related to busulfan conditioning 4 months after BEAM-101 infusion. However, the investigator determined that the death was unrelated to BEAM-101.
The Data Safety Monitoring Committee and FDA reviewed the case.
In all patients dosed, there were no ≥ Grade 3 adverse events (AEs) or serious AEs related to BEAM-101.
Preliminary efficacy data showed that all patients achieved over 60% fetal hemoglobin (HbF, the main oxygen carrier protein in the human fetus) and less than 40% HbS (an abnormal type of hemoglobin that causes sickle cell disease) of non-transfused hemoglobin at Month 1, sustained through all time points.
Markers of hemolysis (destruction of red blood cells) normalized or improved for all patients.
No vaso-occlusive crises (VOCs, painful complication of sickle cell anemia) were reported by investigators following BEAM-101 treatment.
Beam Therapeutics said patient enrollment in the Phase 1/2 trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) is progressing. Site activation globally has continued, and dosing has been completed for the first cohort.
Beam has nominated a development candidate for its ESCAPE technology comprised of two investigational drug products: BEAM-103, an anti-CD117 monoclonal antibody (mAb), and BEAM-104, a cell therapy that includes the same therapeutic edit as BEAM-101 (editing the HBG1/2 genes to elevate fetal hemoglobin), plus an additional edit to CD117 which is designed to prevent binding of BEAM-103, allowing the edited cells to evade suppression by the antibody.
The company intends to advance BEAM-103 and BEAM-104 for development in SCD and beta-thalassemia.
Beam Therapeutics ended the third quarter of 2024 with $925.8 million in cash, cash equivalents, and marketable securities, providing a cash <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41739986/beam-therapeutics-reports-third-quarter-2024-financial-results-and-progress-across-priority-progra" rel="noreferrer noopener">runway into 2027</a>.
Price Action: BEAM stock is down 2.40% at $23.78&nbsp;at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41751557/nvidia-takes-short-lived-lead-over-apple-in-valuation" target="_blank" rel="noreferrer noopener">Nvidia Takes Short-Lived Lead Over Apple In Valuation</a></li>
</ul>

Biotech

Health Care

BEAM

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial

Marqeta Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) shares are trading lower Tuesday on the heels of the company&#8217;s third-quarter financial results. Several analysts also downgraded and lowered price targets on the stock<a href="https://www.benzinga.com/pressreleases/24/11/b41727151/marqeta-reports-third-quarter-2024-financial-results"> following the report</a>.
Q3 Earnings: Marqeta reported third-quarter revenue of $127.97 million, missing analyst estimates of $128.08 million. The company reported a quarterly loss of 6 cents per share, in line with analyst estimates, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue was up 18% year-over-year. Marqeta reported total processing volume of $74 billion, up 30% year-over-year. 
&#8220;In the third quarter our true growth trajectory was back on display as we lapped the Block contract renewal, while continuing to demonstrate operational discipline to fuel strong Adjusted EBITDA,&#8221; said Simon Khalaf, CEO at Marqeta.
&#8220;We combined this with several new product announcements that further enhance the Marqeta platform to provide transformative payment solutions at scale for our expanding customer base.&#8221; 
Marqeta&#8217;s outlook appears to be the main thing weighing on shares on Tuesday. Marqeta expects fourth-quarter revenue growth of 10% to 12%. The company anticipates fourth-quarter profit growth of 13% to 15% and fourth-quarter EBITDA margin of 5% to 7%. 
&#8220;Our fourth quarter guidance reflects several changes that became apparent over the last few months with regards to the heightened scrutiny of the banking environment and specific customer program changes,&#8221; the company said. 
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41753325/wall-street-rallies-on-election-day-palantir-skyrockets-bitcoin-tops-70-000-whats-driving-">Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What&#8217;s Driving Markets Tuesday?</a>
Analyst Changes:
<ul>
<li>Deutsche Bank analyst Bryan Keane downgraded Marqeta from Buy to Hold and lowered the price target from $9 to $4.</li>
</ul>
<ul>
<li>Keybanc analyst Alex Markgraff downgraded Marqeta from Overweight to Sector Weight.</li>
</ul>
<ul>
<li>William Blair analyst Robert Napoli downgraded Marqeta from Outperform to Market Perform.</li>
</ul>
<ul>
<li>Susquehanna analyst James Friedman maintained Marqeta with a Positive and lowered the price target from $9 to $7.</li>
</ul>
<ul>
<li>Wells Fargo analyst Andrew Bauch downgraded Marqeta from Overweight to Equal-Weight and lowered the price target from $7 to $5.</li>
</ul>
<ul>
<li>Morgan Stanley analyst James Faucette maintained Marqeta with an Equal-Weight and lowered the price target from $7 to $5.</li>
</ul>
<ul>
<li>Monness, Crespi, Hardt analyst Gus Gala downgraded Marqeta from Buy to Neutral.</li>
</ul>
<ul>
<li>JPMorgan analyst Tien-Tsin Huang maintained Marqeta with a Neutral and lowered the price target from $6 to $5.</li>
</ul>
<ul>
<li>Mizuho analyst Anthony Crowdell maintains Marqeta with an Outperform and lowered the price target from $7 to $5.</li>
</ul>
MQ Price Action: <a href="http://benzinga.com/quote/mq">Marqeta shares</a> were down 40.4% at $3.55 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Downgrades

Marqeta Stock Sinks On Q3 Earnings, Analyst Downgrades

The growing space exploration industry, fueled by private sector interest and revitalized international competition, presents an intriguing investm...

Rocket Lab (RKLB) Makes Substantial Strides and Plays a Big Role in Exploring the Final Frontier

Rocket Lab Stock: Poised To Ride Neutron Higher

Rocket Lab awarded NASA study contract

Rocket Lab Stock Update: Captain, We Have Liftoff

The Momentum Weekly - Interesting Week As The Market Preps For Earnings Season

LMT, GE, RTX deliver earnings; None crack top 10 in the defense industry per SA quant metrics

KeyBanc analyst Mike Leschock raised the firm's price target on Rocket Lab (RKLB) to $12 from $11 and keeps an Overweight rating on the shares as p...

Rocket Lab price target raised to $12 from $11 at KeyBanc

Recent data suggests that Rocket Lab USA ($RKLB) could be the next big short squeeze. The space exploration company has garnered significant moment...

Is Rocket Lab USA (NASDAQ:RKLB) the Next Big Short Squeeze?

Rocket Lab And Snap Inc: 2 'Bond-Like' Option Trade Ideas Yielding 10%+

Catalyst Watch: Eyes on tech with Apple, Amazon, Alphabet, and Meta reporting

AMZN

ATRO

BDRBF

BMEA

CART

CAVA

CHTR

COHR

DASH

DFEN

DUOL

FFIV

FITE

FVRR

HSBC

IDCC

INTC

INUV

LFVN

LMND

LUMN

LUNR

MGPI

MRNS

MSFT

NVDA

OKLO

OSTX

PAPL

PHUN

PLTR

PTON

QRVO

RDDT

RMLFF

SABR

SAVE

SBUX

SHLD

SNAP

SVCO

TLTFF

UBER

WHLR

Press Releases

Rocket Lab Ships Twin Satellites to Launch Site for NASA Mars Mission

Former Lockheed Martin Chief Financial Officer Joins Rocket Lab Board of Directors

Rocket Lab Sets Launch Date for Second Dedicated Kinéis Mission to Deploy IoT Constellation

Rocket Lab Appoints Chief Operations Officer to Support Company Growth

Rocket Lab Successfully Launches 53rd Electron Mission, Deploys Another Five Satellites for Kinéis

Rocket Lab Completes Second Spacecraft for Varda Space Industries, Advancing In-Space Manufacturing

Rocket Lab Awarded NASA Study Contract to Explore Bringing Rock Samples from Mars to Earth for the First Time

Rocket Lab Announces Date of Third Quarter 2024 Financial Results

Rocket Lab Adds New Mission to 2024 Launch Manifest, Schedules Launch in Coming Days

From Contract to Space in Less Than Ten Weeks: Rocket Lab Launches its 54th Electron Mission

Comments

Rocket Lab USA

매도 수량

Rocket Lab USA (NASDAQ:RKLB) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌